目的：探讨氟哌噻吨美利曲辛（黛力新）与抗心肌缺血治疗对冠心病伴焦虑抑郁患者的疗效和对生活质量的影响。方法：选择96例冠心病伴焦虑抑郁患者，随机平均分为两组，研究组（48例）给予黛力新联合抗心肌缺血治疗，对照组（48例）单纯给予抗心肌缺血治疗。4周后观察临床疗效，同时观察焦虑自评量表和抑郁自评量表评分变化。治疗半年后，评估两组患者的生活质量。结果：研究组心绞痛改善总有效率为91.7%，显著高于对照组的72.9%（P＜0.05）；研究组心电图改善总有效率为89.6%，显著高于对照组的60.4%（P＜0.05）。治疗后，研究组焦虑自评量表和抑郁自评量表评分均较治疗前显著下降，且显著低于对照组治疗后评分（P＜0.05）。研究组患者生活质量评定问卷中各项评分均显著高于对照组（P＜0.05）。结论：对冠心病伴焦虑抑郁患者在常规治疗的基础上给予黛力新治疗，可以显著改善焦虑、抑郁情绪，提高生活质量，值得临床推广和普及。%Objective: The efficacy of Flupentixol melitracen (Deanxit) combined with anti-ischemic for treating with anxiety and depression for the patients with coronary artery disease its impact on quality of life. Methods:96 cases with coronary heart disease associated with anxiety and depression were randomly divided into two groups, the study group (48 cases) was given Deanxit combined with anti-ischemic while the control group (48 cases) was treated with anti-ischemic. The clinical efficacy was observed after 4 weeks, while the anxiety self-rating scale and self-rating depression scale scores were observed. After Six months, the quality of life was assessed. Results:The total effective rate of angina improving in the study group was 91.7% significantly higher than 72.9% of the control group (P<0.05); the total effective rate of ECG improving in the study group was 89.6% significantly higher than 60.4% of the control group (P<0.05 ). After the treatment, the anxiety self-rating scale and self-rating depression scale scores of the study group were significantly lower pre-treatment and the control group (P<0.05). The assessment questionnaire scores for quality of life in the study group were significantly higher than those in the control group (P<0.05). Conclusion: Deanxit combined with the conventional treatment for treating with coronary artery disease for the patients with anxiety and depression can significantly improve the anxiety, depression, and improve quality of life, which is worth to be promoted.
展开▼
